May 1, 2018
Aravax receives $1.9 million investment tranche from the Medical Research Commercialisation Fund
2 May 2018, Melbourne, Victoria – Aravax has received an additional investment of $1.9M from the Australian Medical Research...
top of page
Developing safe, convenient, disease-modifying treatments for food allergies.
.jpg)
News
bottom of page